Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-232-000"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20120911.32.2-232-000"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Mr President, public health is an issue which affects every citizen of the Union, and is an area of work in which the European institutions should be involved. The worrying information which appears from time to time about problems connected with the operations of pharmaceutical firms makes it necessary to provide constant clarification of the principles of pharmacovigilance and of the rules governing the cooperation of all Member States on this matter, particularly because the review carried out by the Commission revealed significant flaws in the current legal system.
Public interest leads me to support the proposed amendments, in particular, the increase in the number of cases requiring the automatic procedure when a Member State considers suspending or withdrawing a pharmaceutical product from sale. Furthermore, provisions making the actions of drug producers more transparent and the longer list of medicines subject to additional post-authorisation monitoring are essential today. I hope that the new legislation will help improve the safety of patients, and this hope was expressed in the common position of all the parliamentary groups. I voted to adopt the report."@en1
|
lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples